Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its AI bone solution, HealthOST, in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the UK, subject to minimum annual license commitments, for an initial three-year term.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans to support clinicians in evaluating and assessing musculoskeletal disease of the spine, including osteoporosis. This technology enables opportunistic detection of vertebral fragility fractures, which are often undiagnosed and can lead to significant morbidity and mortality.
The importance of this agreement is underscored by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in November 2025. NICE recommended HealthOST and a previous version, HealthVCF, among five AI technologies for National Health Service (NHS) use as options to aid opportunistic detection of vertebral fragility fractures. This endorsement from NICE is a critical step in integrating AI-driven diagnostics into routine clinical practice within the UK’s public healthcare system.
By securing an exclusive UK reseller agreement with Vertec Scientific, Nanox AI is positioned to leverage Vertec’s established distribution network and expertise in the UK medical device market. This partnership is expected to accelerate the adoption of HealthOST across NHS trusts and private healthcare providers, potentially improving patient outcomes through earlier detection of osteoporosis and related conditions.
Osteoporosis is a chronic condition that weakens bones, making them fragile and more likely to break. It is often asymptomatic until a fracture occurs, and vertebral fractures are among the most common osteoporotic fractures. Early detection through opportunistic screening of routine CT scans can prompt timely intervention, reducing the risk of subsequent fractures and improving quality of life.
The integration of AI solutions like HealthOST into clinical workflows aligns with the broader trend towards preventive healthcare and value-based medicine. By analyzing existing imaging data without additional radiation exposure or patient burden, AI tools can enhance diagnostic accuracy and efficiency.
Nanox Imaging is focused on driving the world’s transition to preventive healthcare by delivering an integrated, end-to-end medical imaging and healthcare services platform. The company combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of AI algorithms that augment the interpretation of routine CT imaging; Nanox.CLOUD, a cloud-based platform for secure data management and analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts; and Nanox Health IT, which delivers RIS, PACS, AI, dictation, and secure infrastructure solutions.
This exclusive UK reseller agreement represents a strategic move to expand the reach of Nanox.AI’s solutions in a key market, leveraging NICE’s recommendation to drive adoption. For Vertec Scientific, the partnership adds a cutting-edge AI diagnostic tool to its portfolio, enhancing its offering to healthcare providers.
The initial three-year term of the agreement, with minimum annual license commitments, indicates a mutual commitment to establishing HealthOST as a standard tool for opportunistic osteoporosis screening in the UK. As AI continues to transform medical imaging, such collaborations are vital to translating technological advancements into tangible clinical benefits.
